Progression of targeted therapy for colorectal cancer        LIN Feng, LI Yong. Guangdong Provincial People's Hospital ， Guangdong Province Academy of Medical Sciences, Guangzhou 510080, China
Corresponding  author：LIN Feng，E-mail: liyong-lucky@21cn.com
Abstract    Colorectal cancer is one of the most common malignant tumors but the results of conventional chemotherapy have been discouraging. The recent successful development of targeted therapy has brought new hope for patients with colorectal cancer. Two monoclonal antibodies, bevacizumab and cetuximab, that block vascular endothelial growth factor and epithelial growth factor receptor are available widely in clinical practice. The addition of cetuximab or bevacizumab to the chemotherapy  for metastatic colorectal cancer  further improves the outcome.  The combination of chemotherapy with cetuximab or bevacizumab has become standard regimens in advanced colorectal cancer and makes a striking step to prolong the survival time in the past few years. The major achievement for the cetuximab targeted therapy of mCRC is the correlation between k-ras status and the efficacy of anti-EGFR therapy. Molecular targeted therapy plays a more important role in treatment for  colorectal  cancer.